Johnson & Johnson stands alone as a leader across major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a Morningstar Economic Moat Rating of wide.
J&J's strong position in oncology (Darzalex and Carvykti) and next-generation immunology product Tremfya (following Stelara) create a foundation of innovative drugs.
J&J's late-stage drug pipeline could face significant competitive threats, as oncology and immunology remain popular areas for biopharma investment.
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.82 | 13.57 | 44.80 |
Price/Book Value | 7.33 | 6.45 | 8.47 |
Price/Sales | 6.44 | 4.80 | 5.36 |
Price/Cash Flow | 22.07 | 14.16 | 16.10 |
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.73 | 0.55 | 0.71 |
Current Ratio | 1.09 | 0.86 | 1.32 |
Interest Coverage | 25.00 | 11.90 | 4.28 |
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.42% | 14.74% | 6.27% |
Return on Equity (Normalized) | 32.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 20.33% | 21.25% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|l<<w!$^k | LOCK|@&s | $1T | |||
| AbbVie Inc
ABBV
| LOCK|j$bTcn | LOCK|&#F | $459B | |||
| Merck & Co Inc
MRK
| LOCK|^NYh&>$ | LOCK|<y | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|gFSncQ%@ | LOCK|Q?Y | $334B | |||
| Novartis AG ADR
NVS
| LOCK|Mz^&<#Lv | LOCK|y&! | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|!dQnX#!? | LOCK|zQ | $248B | |||
| Amgen Inc
AMGN
| LOCK|&hqM>^&^ | LOCK|#c | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|>Pl?hq | LOCK|q! | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|msVGr> | LOCK|$F | $167B |
United States